-
1
-
-
84858225391
-
2012 Alzheimer's disease facts and figures
-
2012 Alzheimer's disease facts and figures. Alzheimer's Dementia 2012, 8, 131-168; http://www.alz.org/alzheimers-disease-facts-and-figures.asp.
-
(2012)
Alzheimer's Dementia
, vol.8
, pp. 131-168
-
-
-
2
-
-
0036482371
-
Cholinergic drugs in pharmacotherapy of Alzheimers disease
-
Camps, P.; Muñoz-Torrero, D. Cholinergic drugs in pharmacotherapy of Alzheimers disease Mini-Rev. Med. Chem. 2002, 2, 11-25
-
(2002)
Mini-Rev. Med. Chem.
, vol.2
, pp. 11-25
-
-
Camps, P.1
Muñoz-Torrero, D.2
-
3
-
-
1842843753
-
KCNQ potassium channels: Drug targets for the treatment of epilepsy and pain
-
Wickenden, A. D.; Roeloffs, R.; McNaughton-Smith, G.; Rigdon, G. C. KCNQ potassium channels: drug targets for the treatment of epilepsy and pain Expert Opin. Ther. Pat. 2004, 14 (4) 1-13
-
(2004)
Expert Opin. Ther. Pat.
, vol.14
, Issue.4
, pp. 1-13
-
-
Wickenden, A.D.1
Roeloffs, R.2
McNaughton-Smith, G.3
Rigdon, G.C.4
-
4
-
-
0031809240
-
Two new potent neurotransmitter release enhancers, 10,10-bis(4- pyridinylmethyl)-9(10 H)-anthrancenone and 10,10-bis(2-fluoro-4-pyridinylmethyl) -9(10 H)-anthracenone: Comparison to linopirdine
-
Zaczek, R.; Chorvat, R. J.; Saye, J. A.; Pierdomenico, M. E.; Maciag, C. M.; Logue, A. R.; Rominger, D. H.; Earl, R. A. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10 H)-anthrancenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10 H)-anthracenone: comparison to linopirdine J. Pharmacol. Exp. Ther. 1998, 285 (2) 724-730
-
(1998)
J. Pharmacol. Exp. Ther.
, vol.285
, Issue.2
, pp. 724-730
-
-
Zaczek, R.1
Chorvat, R.J.2
Saye, J.A.3
Pierdomenico, M.E.4
MacIag, C.M.5
Logue, A.R.6
Rominger, D.H.7
Earl, R.A.8
-
5
-
-
15444350005
-
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action
-
Earl, R. A.; Zaczek, R.; Teleha, C. A.; Fisher, B. N.; Maciag, C. M.; Marynowski, M. E.; Logue, A. R.; Tam, S. W.; Tinker, W. J.; Huang, S.-M.; Chorvat, R. J. 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action J. Med. Chem. 1998, 41 (23) 4615-4622
-
(1998)
J. Med. Chem.
, vol.41
, Issue.23
, pp. 4615-4622
-
-
Earl, R.A.1
Zaczek, R.2
Teleha, C.A.3
Fisher, B.N.4
MacIag, C.M.5
Marynowski, M.E.6
Logue, A.R.7
Tam, S.W.8
Tinker, W.J.9
Huang, S.-M.10
Chorvat, R.J.11
-
6
-
-
0028889856
-
Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers
-
Pieniaszek, H. J., Jr.; Fiske, W. D.; Saxton, T. D.; Kim, Y. S.; Garner, D. M.; Xilinas, M.; Martz, R. Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers J. Clin. Pharmacol. 1995, 35 (1) 22-30
-
(1995)
J. Clin. Pharmacol.
, vol.35
, Issue.1
, pp. 22-30
-
-
Pieniaszek Jr., H.J.1
Fiske, W.D.2
Saxton, T.D.3
Kim, Y.S.4
Garner, D.M.5
Xilinas, M.6
Martz, R.7
-
7
-
-
78649910308
-
The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels
-
Soh, H.; Tzingounis, A. V. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels Mol. Pharmacol. 2010, 78 (6) 1088-1095
-
(2010)
Mol. Pharmacol.
, vol.78
, Issue.6
, pp. 1088-1095
-
-
Soh, H.1
Tzingounis, A.V.2
-
8
-
-
84864952390
-
-
For information on the Molecular Libraries Probe Production Centers Network (MLPCN)
-
For information on the Molecular Libraries Probe Production Centers Network (MLPCN), see http://mli.nih.gov/mli/.
-
-
-
-
9
-
-
84864938633
-
-
For information on the Vanderbilt Specialized Chemistry Center
-
For information on the Vanderbilt Specialized Chemistry Center, see: http://www.mc.vanderbilt.edu/centers/mlpcn/index.html.
-
-
-
-
10
-
-
84864938635
-
-
ML252 has been declared a probe via the Molecular Libraries Probe Production Centers Network (MLPCN) and is available through the network, see.
-
ML252 has been declared a probe via the Molecular Libraries Probe Production Centers Network (MLPCN) and is available through the network, see: http://mli.nih.gov/mli/.
-
-
-
-
11
-
-
77249122159
-
Physicochemical space for optimum oral bioavailability: Contribution of human intestinal absorption and first-pass elimination
-
Varma, M. V. S.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-Kattan, A.; Troutman, M. D. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J. Med. Chem. 2010, 53 (3) 1098-1108
-
(2010)
J. Med. Chem.
, vol.53
, Issue.3
, pp. 1098-1108
-
-
Varma, M.V.S.1
Obach, R.S.2
Rotter, C.3
Miller, H.R.4
Chang, G.5
Steyn, S.J.6
El-Kattan, A.7
Troutman, M.D.8
-
12
-
-
77956627250
-
Strategic Use of Plasma and Microsome Binding to Exploit in Vitro Clearance in Early Drug Discovery
-
Chang, G.; Steyn, S. J.; Umland, J. P.; Scott, D. O. Strategic Use of Plasma and Microsome Binding To Exploit in Vitro Clearance in Early Drug Discovery ACS Med. Chem. Lett. 2010, 1 (1) 50-63
-
(2010)
ACS Med. Chem. Lett.
, vol.1
, Issue.1
, pp. 50-63
-
-
Chang, G.1
Steyn, S.J.2
Umland, J.P.3
Scott, D.O.4
-
13
-
-
80054878125
-
Discovery, synthesis, and structure-activity relationship of a series of N -aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a novel KCNQ2 and KCNQ4 potassium channel opener
-
Yu, H.; Wu, M.; Townsend, S. D.; Zou, B.; Long, S.; Daniels, J. S.; McManus, O. B.; Li, M.; Lindsley, C. W.; Hopkins, C. R. Discovery, synthesis, and structure-activity relationship of a series of N -aryl-bicyclo[2.2.1] heptane-2-carboxamides: characterization of ML213 as a novel KCNQ2 and KCNQ4 potassium channel opener ACS Chem. Neurosci. 2011, 2, 572-577
-
(2011)
ACS Chem. Neurosci.
, vol.2
, pp. 572-577
-
-
Yu, H.1
Wu, M.2
Townsend, S.D.3
Zou, B.4
Long, S.5
Daniels, J.S.6
McManus, O.B.7
Li, M.8
Lindsley, C.W.9
Hopkins, C.R.10
|